Medical Alert Systems – For Seniors & Inbound Patients

Medical alert systems can save a life.  Especially for in-bound senior citizens and patients with handicaps, etc.

According to this latest study, the 2020 growth of Medical Alert Systems will have significant change from the previous year. The most conservative estimates of the global Medical Alert Systems market size (a most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 6790.3 million in 2019. Over the next five years, the Medical Alert Systems market will register a 7.9% CAGR in terms of revenue, the global market size will reach US$ 9198.5 million by 2025. This speaks volumes for the number of people in need of these types of systems.

With the push of a button, life-saving support can come to the aid to someone in distress. This type of service can create peace of mind for the children of elderly patients or for parents who are forced to go to work leaving their child with a caregiver – yes, even a caregiver can leave the room for a minute for something to happen to the person they are caring.

Selecting a Medical Alert System – Home-Based vs. Mobile

Various medical alert systems have unique features. Home-based systems are designed to work in the home using a landline telephone – all designed to connect to a dispatcher. This type will allow your loved one to speak directly to the dispatcher once they push the button.

A mobile medical alert system work inside the home but also when your loved one leaves their home. This system is ideal for someone who is not frail.

Price

Whether you go with a home-based or mobile medical alert system, there are monthly fees. Remember to ask about adding a fall detection service. Certain devices can also detect when someone has fallen.  It is an added benefit and worth considering.

Conclusion

As more and more people are living longer, many are experiencing various medical problems and other issues that require these systems. It is important to consider all options so that your loved one remains safe and protected.

 

 

 

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”